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Although radiotherapy is effective in early lung cancer, 5-year
overall survival in stage IIIb is less than 10% after radiotherapy
(Koukourakis et al, 1995). The addition of chemotherapy before or
concurrently with irradiation may slightly improve the survival,
but discouraging results have been also reported by randomized
trials (Mattson et al, 1988; Dillman et al, 1990; Morton et al, 1991;
Le Chevalier et al, 1992; Brodin et al, 1996). Forty-five per cent of
patients with locally advanced disease die from local recurrence
without distant metastasis, which suggests that effective local
therapy may prolong disease-free survival or even cure a subset of
patients with non-metastasizing tumour phenotype (Koukourakis
et al, 1995). An effective non-surgical regimen that would increase
the response rate could be also useful in downstaging inoperable
disease or even in improving survival of operable cases.
Recently, several novel agents with remarkable radiosensitizing
properties have been introduced in clinical practice. Taxanes are
inhibitors of microtubule depolymerization (Geuritte-Voegelein
et al, 1991; Ringel et al, 1991). Radiation-sensitizing effects of
docetaxel have been confirmed in vitro (Choy et al, 1992) and are
probably related to the cell synchronization effect to the radio-
sensitive G2/M cell cycle phases (Chaffey et al, 1971). Using the
HL-60 cell line, the sensitizing enhancement ratio at low doses of
docetaxel (0.03 mM), was 2.15 (Choy et al, 1992). In vitro data
showing a putative role of taxanes in phosphorylation of the
bcl-2 anti-apoptotic oncoprotein (Haldar et al, 1996) suggest that
taxanes may further enhance the radiation efficacy by facilitating
the switch-on of the apoptotic machinery after DNA damage by
radiotherapy. Nuclear import of p53 protein after bcl-2 protein
phosphorylation by paclitaxel resulted in induction of apoptosis in
RKO cells treated with g-radiation (Beham et al, 1998). Docetaxel
has also shown remarkable response rates (23–33%) in phase II
studies for advanced non-small-cell lung cancer (NSCLC) (Cerny
et al, 1994; Fossella et al, 1994; Francis et al, 1994).
In a previous phase I/II study we established a well-tolerated
regimen of weekly docetaxel administration together with slightly
accelerated (5-week regimen) concomitant boost radiotherapy for
NSCLC (Koukourakis et al, 1998). The maximum tolerated dose
was 30 mg m–2 week–1. An increased incidence of oesophagitis and
of asthenia was observed, but the encouraging high response rate
(77%) justified further clinical investigation. In the present study
we sought to confirm the high complete response (CR) rate pre-
viously observed in a phase I trial in a new cohort of patients with
locally advanced non-metastatic NSCLC. We made the hypothesis
that the cell synchronization effect of docetaxel may abrogate the
phenomenon of rapid tumour repopulation during radiotherapy so
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that acceleration of radiotherapy could become less important
in the outcome of radiotherapy (Koukourakis et al, 1996).
Conventionally fractionated radiotherapy was therefore used in
this phase II study in order to evaluate whether weekly docetaxel
and non-accelerated radiotherapy could be better tolerated and
equally effective in the treatment of locally advanced NSCLC.
PATIENTS AND METHODS
Recruitment criteria
Thirty five patients with histologically confirmed stage T3, T4/N2,
T3 (TNM; Hermanek and Sobin, 1992) NSCLC entered this phase
II study. Patients should have a PS < 3. Written informed consent
was obtained from all patients. Patients previously treated with
radiotherapy to another than chest site or chemotherapy (including
paclitaxel or docetaxel), completed at least 2 months before
recruitment were also eligible. Patients with known reduced
pulmonary reserve (FEV1 < 800 mL, pO2 < 60, pCO2 > 45),
related to chronic obstructive lung diseases, were excluded from
the study. However, patients with impaired pulmonary reserve
caused by the tumour itself were eligible. Patients with white
blood cells < 2500 ml–1 and platelets (Pt) < 120 000 ml–1 were
excluded. Patients with haemoglobin (Hb) < 10 g ml–1 were trans-
fused until Hb levels raised > 11 g dl–1. Pregnant women or
patients with major heart, liver, renal, psychiatric disease or
haematological malignancies were also excluded. Patients with
known episodes of collapsus as a result of allergic response to
any drug or substance were excluded. Table 1 shows the patient
characteristics.
Pretreatment and treatment evaluation
Baseline studies included physical examination, chest X-rays,
whole blood count (WBC) with differential and platelet count,
complete biochemical profile, bone scan and computerized
tomography (CT) of the chest and upper abdomen. Patients were
followed with WBC, serum urea, and creatinine and liver enzymes
once a week during the radiotherapy period and for 4 weeks there-
after. Chest X-ray and electrocardiogram (ECG) were performed
every 2 weeks. Acute radiation toxicity was registered twice
weekly and radiotherapy delay was enforced in case of grade 3
diarrhoea, cystitis or oesophagitis. The WHO scale (World Health
Organization, 1979) was used to assess chemotherapy and acute
radiation toxicity.
Response to treatment was assessed with CT scan of the chest
lesion on day 25 (to allow eventual modification of the radio-
therapy fields) and 45–60 days after treatment completion.
Duration of response was measured from the time the criteria of
the objective response were first met with CT scan done every
2 months for the first 6 months, and every 3–4 months (or earlier if
necessary) thereafter. CR was defined as 95–100% reduction of
the chest measurable lesion within 2 months after treatment
completion. Given the difficulties of assessing response to radio-
therapy of large masses, any residual scar measuring less than 5%
of the initial tumour volume that did not progress for at least
2 months following response documentation was still considered
as complete response. Similarly, partial and minimal response
refers to 50–95% and 25–49% reduction of tumour dimensions
respectively. Small reduction of tumour dimensions between 0 and
24% that lasted at least 2 months after response documentation
were considered as stable disease. All other cases were considered
as progressive disease regardless of the initial response.
Radiotherapy schedule
Radiotherapy treatment planning was based on recent chest CT
scan. Antero-posterior portals encompassing the primary tumour
and part of the mediastinum were used to deliver a daily dose of
2 Gy (five fractions per week) to a total dose of 44 Gy. The mean
dimensions of these large portals were 264 cm2 (range 210–
355 cm2). Homolateral supraclavicular area was included in cases
with an upper lobe mass. One or two oblique fields limited to the
bulky tumoral area (2 Gy per fraction) were used to increase the
total tumour dose to 64 Gy. The mean dimensions of the booster
fields were 51 cm2 (range 29–124 cm2). Patients with pleural effu-
sion, lung atelectasia or very large tumours were irradiated to the
whole hemithorax using anteroposterior fields, 1.5 Gy daily to a
total dose of 18 Gy. The planned overall treatment time was
6.5 weeks (44 days).
Docetaxel administration
Twelve hours and 30 min before chemotherapy patients received
32 mg oral (p.o.) and 125 mg intravenous (i.v.) bolus methyl-
prednisolone respectively. Ranitidine 300 mg p.o. was given daily
throughout the 6-week treatment. Docetaxel was diluted in 250 ml
normal saline and infused within 20 min. Tropisetron (5 mg i.v.)
was given as anti-emetic treatment. Blood pressure and sympto-
matology assessment were monitored every 5 min during infusion,
and every 15 min for the following hour. No steroids were used
thereafter if no allergic reaction occurred. Whenever allergic
reaction was observed patients were given methyl-prednisolone
(32 mg p.o.) 12 h after chemotherapy.
The docetaxel level was 30 mg m–2 week–1. Six-weekly cycles
of the drug were to be delivered during the 6-week course of radio-
therapy. Neutrophil grade 2 toxicity was to be adjusted with
granulocyte colony-stimulating factor (G-CSF) administration
(300 mg m–2 subcutaneously (s.c.) on Saturday and Sunday every
week) starting immediately after diagnosis and continuing
throughout the radiotherapy period. Our previous experience with
Table 1 Patient characteristics.
Total no. of patients 35
Male:female 33:2
Age, years
Median 64
Range 45–78
WHO PS
Median 1
Range 0–2
TNM-stage
T3,4/N2/M0 10
T3/N3/M0 20
T4/N3/M0 5
Prior treatment
Chemotherapy naive 20
Taxane chemotherapy 6
Platinum chemotherapy 10
Tumour type
Squamous cell 21
Adenocarcinoma 9
Undifferentiated 51794 MI Koukourakis et al
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weekly docetaxel during concomitant boost radiotherapy shows
that the expected haematological toxicity of the docetaxel schedule
usedin the present study is minimal. However, in order to avoid
delays of chemotherapy administration or undesired dose reduc-
tions, a low dose G-CSF schedule was included in the initial
design ofthe study for the rare cases that would present with grade
2 neutropenia. The effectiveness of this low-dose G-CSF schedule
in preventing neutropenia during fractionated chemoradiotherapy
has been established in a previous study of ours (Koukourakis et
al, 1999). Radiotherapy or chemotherapy was not interrupted
unless progression of neutropenia appeared. Grade 3/4 toxicity
was to be followed by 50% dose reduction or chemotherapy inter-
ruption, depending upon severity.
Statistical analysis
The statistical analysis and graph presentation of survival curves
was performed using the GraphPad Prism 2.01 version package.
Statistics between variables were performed using the Fisher’s
exact test or the paired two-tailed t-test, as appropriate. Survival
curves were plotted using the method of Kaplan and Meier.
P values < 0.05 were considered to be statistically significant.
RESULTS
Non haematological docetaxel-related toxicity
Severe hypersensitivity reactions during docetaxel infusion were
seen in 2/35 patients leading to the interruption of the infusion.
Methyl-prednizolone 250 mg i.v. were immediately given. Both
patients received their treatment 30 min later with no further
complications. Hot flushes were observed in 11/35 (31%) cases.
Steroid-related toxicity was minimal since the high dose of
methyl-prednizolone was restricted to 1 day per week.
Prophylactic administration of ranitidine 300 mg daily was given
for 45 days, starting from the beginning of treatment. Transient
increase in blood glucose levels never required the use of insulin.
Table 2 shows the non-haematological toxicity. Neurosensory
toxicity grade 1 was observed in 4/35 (11%) patients during the
3rd–5th cycle and regressed 2–4 weeks after therapy. Mild
asthenia was constantly observed. Asthenia was the only reason
for a 1-week treatment delay in 5/35 (17%) patients. Asthenia,
together with grade 2 oesophagitis, was the reason of a 2-week
treatment delay in 3/35 (8.5%) patients. Anorexia and taste alter-
ation were observed in all 35 patients and were the only side-
effects of therapy in 3/35 (8%) patients. The mean weight loss was
4 kg (range 3–6). Grade 1 alopecia was observed in 25/35 (71%)
and grade 2 in 2/35 (6%) patients. Fever up to 39°C (grade 2),
without confirmation of infection, was observed in 5/35 (14%)
patients during the 3rd–4th week. Omission of docetaxel for
1 week resulted in normalization of the body temperature within
3–5 days. Grade 2 hypotension was observed in 3/35 patients
(8%). Three patients (8.5%) developed bilateral grade 2 leg
oedema and 3/35 (8.5%) pleural effusion during the 4th week of
therapy. Pleural effusion was treated with furosemide and spirolac-
tone and was resolved within 4–8 weeks after therapy. Hot flushes
were seen in 5/35 (14%) patients. No headache, arthralgia-
myalgia, nausea-vomiting, diarrhoea, mucositis or nail disorders
were observed.
‘In-field’ radiotherapy-related toxicity
Radiation-induced grade 3 oesophagitis that resulted in a 1-week
treatment delay was observed in 6/35 patients (17%). Two-week
treatment delay due to severe oesophagitis was necessary in
another 6/35 (17%) patients, where pharyngo-oesophageal
candidiasis was also confirmed in three patients. In 5/6 patients
the oesophagitis started during the 3rd–4th week of treatment and
regressed within 1 week following treatment interruption.
However, grade 3 oesophagitis recurred during the 5th–6th week
of therapy enforcing further treatment delay. Patients were treated
with anti-fungal p.o. therapy and analgesics. ‘In-field’ grade 2
radiation skin toxicity was observed in 2/35 (4%) patients.
Twenty eight cases completed 8–21 months of follow-up. One
patient (3.7%) died from radiation pneumonitis 4 months after
Table 2 Haematological, non-haematological toxicity and radiotherapy
delay in 35 patients with stage IIIb non-small cell lung cancer treated with
standard fractionation of radiotherapy and weekly docetaxel (30 mg m–2)
chemotherapy
Grade RT delaya
0/1 2 3 4 ≤ 7 days > 7 days
Anorexia 35 0 0 0 0 0
Asthenia 27 8 0 0 5 3
Alopecia 33 2 0 0 0 0
Fever 30 5 0 0 5 0
Hot-flushes 11 0 0 0 0 0
Oesophagitis 18 5 12 0 8 6
Fungal infection 32 3 0 0 0 3
Cough 21 14 0 0 0 0
Radiation pneumonitis 27 4 3 1 (late toxicity)
Hypotenstion 32 3 0 0 0 0
Leg oedema 33 2 0 0 0 0
Pleural effusion 32 3 0 0 0 0
Neurosensory 4 0 0 0 0 0
Neutropenia 3 2 0 0 0 0
Haemoglobin 35 0 0 0 0 0
Platelets 35 0 0 0 0 0
Lymphocytes 0 0 5 30 0 0
a Number of patients for which the reported toxicity significantly contributed to
the enforcement of radiotherapy delay.
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Figure 1 Kaplan–Meier survival curves in 35 patients with stage IIIb non-
small-cell lung carcinoma treated with conventionally fractionated
radiotherapy and weekly 30 mg m–2 of docetaxelDocetaxel and radiotherapy for lung cancer 1795
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radiotherapy. Seven out of 28 (25%) developed localized
pulmonary fibrosis. Mild exertional dyspnoea was present in 3/7
patients, but there was no need for oxygen support in any of the
patients (pO2 > 60 mmHg). No patient developed radiation-related
neurological or cardiac late toxicity.
Haematological toxicity
Haemoglobin and neutrophil toxicity was minimal in all cohorts
(Table 2). Grade 2 neutropenia was observed in 2/35 patients
(5.7%) during the 4th week of therapy and received G-CSF
prophylactically (5 mg kg–1 day–1 s.c. for 4 days). No platelet
toxicity was observed. Severe lymphocytopenia was observed: the
lymphocyte counts dropped from 1230 ± 532 dl–1 down to
498  ± 213 dl–1 during the 4th week (P = 0.0003). Monocyte counts
were also decreased from 567 ± 211 dl–1 to 198 ± 120 dl–1
(P = 0.002).
Response and survival
Complete response of the chest disease was observed in 12/35
(34%) patients and partial response in 16/35 (46%). The overall
response rate was 80% (95% confidence interval (CI) 55–88%).
Minimal response was observed in 4/35 (11%) patients and stable
disease in the remaining 3/35 (8.5%).
We further analysed the CR rate in three groups of patients
according to the overall treatment time (Table 3). Eight out of 18
(44%) patients that did not interrupt their treatment had a CR vs
3/11 (27%) and 1/6 (17%) of patients that interrupted their treat-
ment for 1 and 2 weeks respectively. Although the difference was
not statistically significant (P = 0.19), there was a trend of a
shorter overall treatment time to associate with a higher CR rate.
Eight out of 35 (23%) patients are alive with no evidence of
disease 13–23 months after therapy. Twelve out of 35 died from
local progression (five with distant metastasis), 14/35 from distant
metastases (without evidence of local relapse) and one from
radiation-induced pneumonitis. The Kaplan–Meier survival curve
is shown in Figure 1. The median overall survival time was 12
months. The overall survival and the local progression-free
survival at 1 year was 48% and 60% respectively.
DISCUSSION
Docetaxel has shown substantial activity against NSCLC (Cerny
et al, 1994; Fossella et al, 1994; Francis et al, 1994). In a previous
phase I/II study we established a well-tolerated docetaxel scheme
that could be administered concurrently with radiotherapy in
patients with NSCLC (Koukourakis et al, 1998). Weekly doses up
to 30 mg m–2 were well-tolerated with minimal haematological
toxicity and without severe asthenia. This regimen delivers a total
dose of 90 mg m–2 within 3 weeks, which is close to the maximum
tolerated dose of docetaxel given as monotherapy (Tomiak et al,
1994). In a recent study by Maner et al (1998) a lower dose of
docetaxel (20 mg m–2) administered weekly with concomitant
chest radiotherapy was suggested for phase II trials. However, in
our phase I/II study the dose of 30 mg m–2 weekly, together with
concomitant boost radiotherapy, was well-tolerated. The high inci-
dence of radiation-induced oesophagitis was not considered to be a
major problem for this dose level to be tested in subsequent phase
II trials. The 27% CR rate observed further encouraged the
conducting of a pure phase II study.
In order to reduce the high rate of oesophagitis the concomitant
boost-accelerated radiotherapy technique was replaced by a stan-
dard fractionation 6-week regimen. Thirty-five patients with stage
IIIb NSCLC were enrolled in the study. The main toxicity
observed was oesophagitis, which enforced a 2-week treatment
delay in 6/35 (17%) patients and a minor treatment delay of 3–7
days in another 8/35 (23%) patients. Asthenia was frequent and
often coincided with the onset of oesophagitis. In a previous study
of docetaxel combination with accelerated radiotherapy (5-week
regimen) (Koukourakis et al, 1998) the incidence of asthenia and
oesophagitis was similar to the one observed in the present study,
showing that standard fractionation does not improve the tolera-
bility of the regimen. Complete response of the chest disease was
observed in 12/35 (34%) patients and partial response in 16/35
(46%), which are similar to previously reported results
(Koukourakis et al, 1998).
In a previous study we showed that the local control of disease
and survival of patients with NSCLC depends on the overall treat-
ment time (Koukourakis et al, 1996). We observed that in locally
advanced tumours if the radiotherapy schedule extends beyond
35 days, 0.75 Gy from each radiotherapy fraction is consumed to
compensate for rapid tumour repopulation. In the present study we
made the hypothesis that docetaxel may abrogate the role of
overall treatment time. However, despite the small number of
cases, there was a trend for the CR to be more frequently observed
in patients who accomplished their treatment without interruption
(44 days). It could be therefore suggested that further trials with
docetaxel-based radiochemotherapy should take into account
the adverse effect of prolonged radiotherapy treatment time.
Accelerated radiotherapy combination with docetaxel may result
in higher CR rate. Given the high mucosal toxicity and asthenia
observed, support with cytoprotective agents such as amifostin
(Koukourakis, 1998), or even granulocyte–macrophage CSF
(Throuvalas et al, 1995) may prove of importance in the feasibility
of such a regimen.
The survival figures obtained in the present study are encour-
aging. The 48% overall survival and the 60% local progression-
free survival at 1 year are similar to the results reported in a
randomized trial of radiotherapy with concurrent daily cis-plati-
num (54% and 59% respectively) (Shaake-Koning et al, 1992).
Our previous experience with radiotherapy alone shows that the
1-year survival in stage IIIb NSCLC is lower than 20%
(Koukourakis et al, 1995, 1996). It should be stressed that all
patients recruited in the present study had large tumoural burden
and 15/35 (43%) of them had disease unresponsive to previous
chemotherapy.
We conclude that docetaxel combination with radiotherapy is a
promising approach for the management of locally advanced
NSCLC. The high complete response rate observed encourages
the use of this combination as a preoperative regimen in stage
Table 3 Response rate after 64 Gy of standard fractionation of radiotherapy
given together with weekly docetaxel, according to overall treatment time
Overall treatment time No. of patients CR (%) PR (%) NR (%) P-value
(days)
44–47 18 8 (44) 7 (39) 3 (17)
50–54 11 3 (27) 7 (63) 1 (10) >0.12
57–61 6 1 (17) 2 (33) 3 (50)1796 MI Koukourakis et al
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IIb/IIIa. It is also anticipated that about 70% of patients with stage
IIIb disease will show substantial reduction of the tumour burden,
which may be important in the re-evaluation of the disease oper-
ability. Further investigation is required to assess the feasibility and
efficacy of docetaxel combination with accelerated and/or hyper-
fractionated radiotherapy schedules supported with cytoprotection.
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